Cimeio Therapeutics

This therapy has the potential to be a universal treatment for patients with blood cancers, and significantly improve the outcomes for those hardest to treat forms such as AML.

They have demonstrated that its possible to safely administer a highly effective CD45 ADC to eliminate aggressive leukemia cells in mice, while preserving hematopoiesis through the administration of CD45 epitope shielded HSCs.

Congratulations to our founder Lukas Jeker, Romina Matter-Marone and the teams at @Jekerlab and @Cimeio on the publication of their work on CD45 in this week’s issue of @Nature. cimeio.com/2024/05/22/cim…

This program serves as the basis for a novel treatment approach for patients with T cell malignancies, and aiding in improving the durability of allogeneic CAR T cells.

For those attending this week's hashtag#ASGCT meeting, please join our CSO Stefanie Urlinger at poster no. 1778 beginning at 5:30 PM on Friday, where she will be presenting the first data on our CD52 program. cimeio.com/2024/05/09/cim…

Links to abstracts ashpublications.org/blood/article/… ash.confex.com/ash/2023/webpr…

This weekend we presented data at #ASH23 for our CD45 program, showing full tumor eradication in an aggressive AML cell line in vivo. These data serve as POC for a program that could one day transform the treatment of AML cimeio.com/2023/12/11/cim…

In the second, we demonstrate how our epitope edited CD33 HSCs are shielded from CD33 directed immunotherapy depletion. CD33 represents the fourth target we have epitope edited to prevent paired immunotherapy depletion while maintaining its function.

We are pleased to announce that we will be presenting two posters at this year’s ASH meeting. In the first, we demonstrate that our CD45 ADC effectively depletes AML cells, while our shielded HSCs are fully protected. #ASH23 cimeio.com/2023/11/03/cim…

Today we announced a collaboration with Saar Gill and @carlhjune at @PennMedicine to develop and test a CD45 CAR T cell that pairs with our CD45 shielded HSCs. This ‘Universal CAR T’ could be used to treat any type of blood cancer or autoimmune disease. cimeio.com/2023/10/16/cim…

@PrimeMedicine This collaboration brings together industry leading protein engineering and genome editing, with the potential to deliver safer, curative therapies for patients

We are very pleased to announce a research collaboration with @PrimeMedicine to develop CD117 shielded products for AML/MDS and rare genetic diseases (ex-SCD). cimeio.com/2023/06/22/pri…

This program could serve as a universal approach to reset the hematopoietic system for hematologic malignancies or severe autoimmune diseases.

Our in vivo data showed efficient engraftment and differentiation of our engineered CD45 engineered HSCs, as well as shielding and strong enrichment in combination with our CD45 immunotherapy.

We are pleased to present the first data from our CD45 shielded cell program at this week's #ASGCT meeting in Los Angeles. The poster number is 899, and will be presented from 12:00-2:00 PT on Thursday, May 18. cimeio.com/2023/05/16/cim…

A hearty congratulations to Jeff for this well deserved recognition! twitter.com/AtUcsf/status/…

Very nice @biocentury article covering the emerging cellular shielding field, including @cimeio's recent abstracts for CD117 and CD123, along with those for @BeamTx, @carlhjune, and @Genovese_Lab

Congratulations to Romina Matter and Emmanuelle Landmann for presenting our first data demonstrating proof-of-concept for our SCIP platform this weekend at #ASH2022! cimeio.com/2022/12/11/cim…

Excited to announce that we've been granted broad IP that covers the shielding of cells from immunotherapy depletion. This foundational IP protects our SCIP platform and enables us to develop curative therapies for patients with life threatening diseases cimeio.com/2022/11/28/cim…

We're very pleased to present the first data for our SCIP (Shielded Cell & Immunotherapy Pairs) platform at #ASH2022. Two abstracts covering our CD117 and CD123 programs demonstrate POC in vivo and serve as the basis for a broad development pipeline. cimeio.com/2022/11/03/cim…